Literature DB >> 36034099

Management System Approach for Addressing Biosafety and Biosecurity of Emerging Pathogens in a Biosafety Level-3 Core Facility.

Tessy Joseph1.   

Abstract

Introduction: The biosafety level-3 (BSL-3) core facility (CF) at Yong Loo Lin School of Medicine (NUS Medicine) in National University of Singapore (NUS) has adopted international standards and guidelines to establish a biorisk management (BRM) system that helps to improve its BRM system and consistently minimize the risks to employees, the public, and the environment to an acceptable level while working with SARS-CoV-2.
Methods: When the NUS Medicine BSL-3 CF started its operations, the Occupational Health and Safety Assessment Series 18001:2007 and the CEN Workshop Agreement 15793:2011 guidelines were used to establish its first BRM framework. The BRM framework provided the roadmap of how to organize, systematically manage, and structure the various biorisk programs that was then modified according to International Organization for Standardization 35001:2019 during the coronavirus disease 2019 pandemic in 2020 to address the specific circumstances.
Results: Adopting a management system approach allowed BSL-3 CF to efficiently manage its BRM even during unpredicted emerging pandemic situations. It resulted in integrating a risk management process into daily laboratory operations and ongoing identification of hazards, prioritization of risks, and the establishment of risk mitigation measures specific to SARS-CoV-2. In addition, the implementation of a BRM system in the BSL-3 CF has increased biorisk awareness among BSL-3 CF users and encouraged every stakeholder to take ownership of their activities, and continual improvements in mitigation of biorisks. Discussion: This article summarizes the systematic approaches and major elements of the BRM systems adopted by NUS Medicine BSL-3 CF for the implementation of biosafety and biosecurity precautions, and control measures to minimize the risk of research activities using various RG3 biological agents including SARS-CoV-2. Copyright 2021, ABSA International 2021.

Entities:  

Keywords:  SARS-CoV-2; biosafety; biosecurity; emerging pathogens; management system; risk assessment

Year:  2021        PMID: 36034099      PMCID: PMC9134332          DOI: 10.1089/apb.2021.0007

Source DB:  PubMed          Journal:  Appl Biosaf        ISSN: 1535-6760


  5 in total

1.  Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel.

Authors:  J Michael Miller; Rex Astles; Timothy Baszler; Kimberle Chapin; Roberta Carey; Lynne Garcia; Larry Gray; Davise Larone; Michael Pentella; Anne Pollock; Daniel S Shapiro; Elizabeth Weirich; Danny Wiedbrauk
Journal:  MMWR Suppl       Date:  2012-01-06

2.  Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to COVID.

Authors:  Mario Coccia
Journal:  Sci Total Environ       Date:  2020-04-20       Impact factor: 7.963

3.  Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.

Authors:  Alexa M Kaufer; Torsten Theis; Katherine A Lau; Joanna L Gray; William D Rawlinson
Journal:  Pathology       Date:  2020-09-30       Impact factor: 5.306

Review 4.  Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea.

Authors:  Ki Ho Hong; Sang Won Lee; Taek Soo Kim; Hee Jae Huh; Jaehyeon Lee; So Yeon Kim; Jae Sun Park; Gab Jeong Kim; Heungsup Sung; Kyoung Ho Roh; Jae Seok Kim; Hyun Soo Kim; Seung Tae Lee; Moon Woo Seong; Namhee Ryoo; Hyukmin Lee; Kye Chul Kwon; Cheon Kwon Yoo
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

Review 5.  Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review.

Authors:  Francesco Di Gennaro; Damiano Pizzol; Claudia Marotta; Mario Antunes; Vincenzo Racalbuto; Nicola Veronese; Lee Smith
Journal:  Int J Environ Res Public Health       Date:  2020-04-14       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.